Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
Jack Shuang Hou, Diagnostic Executive, Microfluidics and Immunoassay Specialist, shared a post on LinkedIn:
“Novo Nordisk to Present New Haemophilia Data at ISTH 2026 Highlighting Investigational Denecimig (Mim8)
Novo Nordisk will present new clinical and real-world data across its haemophilia portfolio at the ISTH 2026 Congress, featuring multiple analyses of investigational denecimig (Mim8) and new pediatric data for Alhemo (concizumab).
The presentations reinforce Novo Nordisk’s long-standing commitment to advancing innovation in rare bleeding disorders.
1.Denecimig (Mim8) Highlights
Phase 3 FRONTIER4 long-term data
- Adults, adolescents and children
- Patients with or without FVIII inhibitors
- Once-monthly, every-2-week and weekly prophylaxis evaluated
- Long-term efficacy, safety and patient-reported outcomes
2.Alhemo (Concizumab)
First Phase 3 explorer10 pediatric data
- Children younger than 11 years with haemophilia A or B and inhibitors
- Efficacy, safety and PK and PD results
- Pediatric indication remains investigational
3.Looking Ahead
Novo Nordisk will also present real-world evidence, physician preference studies and mechanistic research while continuing regulatory review of denecimig, following its U.S. BLA submission in 2025.
Leadership Perspective
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, said the company’s research reflects decades of listening to the haemophilia community while advancing person-centered innovation to improve care.
My takeaway
Novo Nordisk continues to build one of the industry’s most comprehensive haemophilia portfolios. With flexible prophylactic dosing, expanding pediatric evidence, and next-generation bispecific antibodies like denecimig, the company is positioning itself to further reshape long-term management across the full spectrum of haemophilia A.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering